Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Essent Biologics debuts stem cell offerings for biopharma and cell therapy research

By Brian Buntz | June 28, 2021

Essent BiologicsAlloSource (Centennial, Colo.), a central U.S. provider of allograft providers, has founded a separate nonprofit known as Essent Biologics to provide human-derived biomaterials for research. Essent has recently launched a human mesenchymal stem cells (hMSCs) offering for a range of research applications. 

“The mission for the nonprofit is to maximize that gift of donation,” said Derek Mathers, head of business development at Essent Biologics. 

Each vial of hMSCs contains more than one million cells after thawing. They have a passage level of P0 or P1 to ensure potency.

The company offers stem cells produced under current Good Manufacturing Practices (cGMP) and in accordance with International Society for Cell & Gene Therapy (ISCT) guidelines. 

The company’s scientists have discovered a method for isolating cells and scaffold materials from tissue donation. The resulting cells are the first human-derived cell product that doesn’t use animal products or antibiotics in their processing, Mathers said. 

From a single donation, Essent Biologics can produce approximately 1.5 billion primary cells, and approximately 1 kg of scaffold materials for regenerative medicine purposes.

Essent can provide information about the origin of stem cells. “Traditionally, it’s been very difficult to tell exactly what donor human mesenchymal stem cells came from,” Mathers explained. “Our whole vision is to pair real human tissue from the donor with comprehensive donor information but still protect that donor’s identity,” he said. 

Essent can specify, for instance, if a donor was a smoker, their BMI and lifestyle factors, and whether they had any specific diseases. “We typically provide healthy cells,” but human disease tissue can potentially enable researchers to reduce or eliminate the need for testing with animal products. “Human cells are the most relevant biology for human therapies that they’re developing,” Mathers concluded. 


Filed Under: Drug Discovery, Drug Discovery and Development
Tagged With: allograft, AlloSource, biomaterials, cGMP, Essent Biologics, Good Manufacturing Practices, hMSCs, human mesenchymal stem cells
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE